Download PDF
Horm Metab Res 2018; 50(06): 462-468
DOI: 10.1055/a-0620-8517
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Correlation Between the Responses to Growth Hormone (GH) Treatment During Childhood and Adulthood in a Monocentric Cohort of GH-Deficient Patients

Sarah Thilmany   *
1   Department of Endocrinology, University Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium
,
Leila Mchirgui   *
2   Pediatric Endocrinology Unit, University Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium
,
Chloé Brunelle
2   Pediatric Endocrinology Unit, University Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium
,
Véronique Beauloye
2   Pediatric Endocrinology Unit, University Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium
,
Dominique Maiter
1   Department of Endocrinology, University Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium
,
Orsalia Alexopoulou
1   Department of Endocrinology, University Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium
› Author Affiliations
Further Information

Publication History

received 18 December 2017

accepted 12 April 2018

Publication Date:
08 June 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Our aim was to analyze a cohort of patients with childhood-onset growth hormone deficiency (GHD) to evaluate if there is some correlation between the response to GH treatment during childhood and adulthood, respectively. This was an observational retrospective monocentric cohort study of 47 patients treated with GH during childhood and adulthood. Changes in growth parameters during childhood were compared with the increase of IGF-I z-score and other indexes of GH response (body composition, lipid profile) after 1 year of treatment in adulthood. The only significant positive correlation was observed between final growth velocity during the last year of childhood GH treatment and increase in IGF-I z-score in GH-treated adults (r=0.592, p=< 0.01). No correlation was observed between growth-promoting effects of GH as child and metabolic changes induced by GH as adult. We also observed a negative correlation between weight at the end of childhood GH treatment and the IGF-I response during first year of treatment in adults (r=− 0.335, p <0.05). No significant positive correlation could be observed between the main parameters that evaluate response to GH treatment in children and adults. However, the final growth velocity, which may be considered as one of the main criteria of end of GH treatment in children, was identified as parameter that could predict future response to GH treatment in adulthood.

Key words

GH responsiveness - growth velocity - IGF-I - body composition

* These authors contributed equally to this work


Supplementary Material

 

  • References

  • 1 Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, Hardin DS, Kemp SF, Lawson M, Radovick S, Rosenthal SM, Silverman L, Speiser P. Update of guidelines for the use of growth hormone in children: The Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003; 143: 415-421
    CrossrefPubMedGoogle Scholar
  • 2 Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the research society. J Clin Endocrinol Metab 2000; 85: 3990-3993
    PubMedGoogle Scholar
  • 3 De Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995; 16: 63-86
    CrossrefPubMedGoogle Scholar
  • 4 Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1587-1609
    CrossrefPubMedGoogle Scholar
  • 5 Carroll PV, Christ ER. the members of growth hormone research society scientific committee. Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sönksen PH, Tanaka T, Thorner M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. J Clin Endocrinol Metab 1998; 83: 382-395
    CrossrefPubMedGoogle Scholar
  • 6 Appelman-Dijkstra N, Claessen K, Roelfsema F, Pereira A, Biermasz N. Long-term effects of recombinant human GH replacement in adults with GH deficiency: A systematic review. Eur J Endocrinol 2013; 169: R1-R14
    CrossrefPubMedGoogle Scholar
  • 7 Schonau E, Westermann F, Rauch F, Stabrey A, Wassmer G, Keller E, Bramswig J, Blum WF. A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur J Endocrinol 2001; 144: 13-20
    CrossrefPubMedGoogle Scholar
  • 8 Albertsson-Wikland K, Kristrom B, Rosberg S, Svensson B, Nierop AFM. Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Pediatr Res 2000; 48: 475-484
    CrossrefPubMedGoogle Scholar
  • 9 Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999; 84: 1174-1183
    CrossrefPubMedGoogle Scholar
  • 10 Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: Analysis of a large international database. J Clin Endocrinol Metab 2006; 91: 2047-2054
    CrossrefPubMedGoogle Scholar
  • 11 De Ridder MA, Stijnen T, Hokken-Koelega AC. Prediction of adult height in growth-hormone-treated children with growth hormone deficiency. J Clin Endocrinol Metab 2007; 92: 925-931
    CrossrefPubMedGoogle Scholar
  • 12 Straetemans S, Roelants M, Thomas M, Rooman R, De Schepper J. Reference curve for the first-year growth response to growth hormone treatment in prepubertal children with idiopathic growth hormone deficiency: Validation of the KIGS first-year growth response curve using the Belgian Register for the Study of Growth and Puberty Problems. Horm Res Paediatr 2014; 81: 343-349
    CrossrefPubMedGoogle Scholar
  • 13 Barbosa EJ, Koranyi J, Filipsson H, Bengtsson BA, Boguszewski CL, Johannsson G. Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults. Eur J Endocrinol 2010; 162: 869-878
    CrossrefPubMedGoogle Scholar
  • 14 Feldt-Rasmussen U, Brabant G, Maiter D, Jonsson B, Toogood A, Koltowska-Haggstrom M, Krogh Rasmussen A, Buchfleder M, Saller B, Biller MK. Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak. Eur J Endocrinol 2013; 168: 733-743
    CrossrefPubMedGoogle Scholar
  • 15 Monson JP. Long-term experience with GH replacement therapy: Efficacy and safety. Eur J Endocrinol 2003; 148: 9-14
    CrossrefPubMedGoogle Scholar
  • 16 Cook D, Rose S. A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary 2012; 15: 301-310
    CrossrefPubMedGoogle Scholar
  • 17 Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005; 152: 165-170
    CrossrefPubMedGoogle Scholar
  • 18 Tanner JM. Standards for children’s height at ages 2-9 years allowing for height of parents. Arch Dis Child 1970; 45: 755-762
    CrossrefPubMedGoogle Scholar
  • 19 http://www.vub.ac.be/groeicurven website accessed 18/10/2017
    PubMed
  • 20 Brabant G, Von zur Mühlen A, Wüster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthén L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P. Serum Insulin-Like Growth Factor I Reference Values for an Automated Chemiluminescence Immunoassay System: Results from a Multicenter Study. Horm Res 2003; 60: 53-60
    CrossrefPubMedGoogle Scholar
  • 21 Alexopoulou O, Bex M, Kamenicky P, Bessomo Mvoula A, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: A study in 148 patients. Pituitary 2014; 17: 81-89
    CrossrefPubMedGoogle Scholar
  • 22 Ranke MB, Lindberg A. KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disorders: Guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010; 95: 1229-1237
    CrossrefPubMedGoogle Scholar
  • 23 Johannsson G, Bjarnason R, Bramnert M, Carlsson LMS, Degerlad M, Manhem P, Rosen T, Thoren M, Bengtsson BA. The Individual Responsiveness to Growth Hormone (GH) Treatment in GH-Deficient Adults Is Dependent on the Level of GH-Binding Protein, Body Mass Index, Age, and Gender. J Clin Endocrinol Metab 1996; 81: 1575-1581
    PubMedGoogle Scholar
  • 24 Hansen TK, Jørgensen JO, Christiansen JS. Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age. J Clin Endocrinol Metab 2002; 87: 2185-2193
    CrossrefPubMedGoogle Scholar
  • 25 Van der Klaauw AA, Van der Straaten T, Baak-Pablo R, Biermasz NR, Guchelaar HJ, Pereira AM, Smit JWA, Romijn JA. Influence of the d3-Growth Hormone (GH) Receptor Isoform on Short-Term and Long-Term Treatment Response to GH Replacement in GH-Deficient Adults. J Clin Endocrinol Metab 2008; 93: 2828-2834
    CrossrefPubMedGoogle Scholar
  • 26 Barbosa EJ, Palming J, Glad CAM, Filipsson H, Koranyi J, Bengtsson BA, Carlsson LMS, Boguszewski CL, Johannsson G. Influence of the Exon 3-Deleted/Full-Length Growth Hormone (GH) Receptor Polymorphism on the Response to GH Replacement Therapy in Adults with Severe GH Deficiency. J Clin Endocrinol Metab 2009; 94: 639-644
    CrossrefPubMedGoogle Scholar
  • 27 Ouni M, Castell AL, Linglart A, Bougnères P. Genetic and epigenetic modulation of growth hormone sensitivity studied with the IGF-1 generation test. J Clin Endocrinol Metab 2015; 100: 919-925
    CrossrefPubMedGoogle Scholar
  • 28 Mukherjee A, Monson JP, Jönsson PJ, Trainer PJ, Shalet SM. Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. J Clin Endocrinol Metab 2003; 88: 5865-5870
    CrossrefPubMedGoogle Scholar
  • 29 Drake WM, Coyte D, Camacho-Hübner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998; 83: 3913-3919
    CrossrefPubMedGoogle Scholar
  • 30 Murray RD, Howell SJ, Lissett CA, Shalet SM. Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency. Clin Endocrinol 2000; 52: 537-542
    CrossrefPubMedGoogle Scholar
  • 31 Meyer S, Haist M, Schaefer S, Ivan D, Ittner JR, Nawroth PP, Plöckinger U, Stalla GK, Tuschy U, Weber MM, Weise A, Pfützner A, Habbe N, Kann PH. Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults. Pharmacogenomics 2008; 9: 1017-1026
    CrossrefPubMedGoogle Scholar
  • 32 Thorén M, Hilding A, Baxter RC, Degerblad M, Wivall-Helleryd IL, Hall K. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1997; 82: 223-228
    PubMedGoogle Scholar
  • 33 Ezzat S, Fear S, Gaillard RC, Gayle C, Marcovitz S, Mattioni T, Nussey S, Rees A, Svanberg E. Circulating IGF-I levels in monitoring and predicting efficacy during long-term GH treatment of GH-deficient adults. Eur J Endocrinol 2003; 149: 499-509
    CrossrefPubMedGoogle Scholar
  • 34 Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997; 82: 550-555
    PubMedGoogle Scholar
  • 35 Columb B, Smethurst LE, Mukherjee A, Jostel A, Shalet SM, Murray RD. GH sensitivity of GH-deficient adults is dependent on gender but not timing of onset. Clin Endocrinol (Oxf) 2009; 70: 281-286
    CrossrefPubMedGoogle Scholar
  • 36 Straetemans S, De Schepper J, Thomas M, Verlinde F, Rooman R. and the members of BESPEED. Validation of prediction models for near adult height in children with idiopathic growth hormone deficiency treated with growth hormone: A Belgian Registry Study. Horm Res Paediatr 2016; 86: 161-168
    CrossrefPubMedGoogle Scholar
  • 37 Thomas M, Massa G, Bourguignon JP, Craen M, De Schepper J, de Zegher F, Dooms L, Du Caju M, François I, Heinrichs C, Malvaux P, Rooman R, Thiry-Counson G, Vandeweghe M, Maes M. Final height in children with idiopathic growth hormone deficiency treated with recombinant human growth hormone: The Belgian experience. Horm Res 2001; 55: 88-94
    CrossrefPubMedGoogle Scholar
  • 38 Darendeliler F, Lindberg A, Wilton P. Response to Growth Hormone Treatment in Isolated Growth Hormone Deficiency versus Multiple Pituitary Hormone Deficiency. Horm Res Paediatric 2011; 76 (Suppl. 01) 42-46
    PubMedGoogle Scholar
  • 39 Cutfield W, Lindberg A, Albertsson Wikland K, Chatelain P, Ranke MB, Wilton P. Final height in idiopathic growth hormone deficiency: The KIGS experience. KIGS International Board. Acta Paediatr Suppl 1999; 88: 72-75
    PubMedGoogle Scholar
  • 40 Ranke MB, Lindberg A, Chatelain P, Wilton P, Price DA, Albertsson-Wikland K. The potential of prediction models based on data from KIGS as tools to measure responsiveness to growth hormone. Hormone Research 2001; 55 (Suppl. 02) 44-48
    CrossrefPubMedGoogle Scholar
  • 41 Blethen SL, Baptista J, Kuntze J, Foley T, Lafranchi S, Johanson A. Adult Height in Growth Hormone (GH)-Deficient Children Treated with Biosynthetic GH. J Clin Endocrinol Metab 1997; 82: 418-420
    CrossrefPubMedGoogle Scholar
  • 42 Ranke MB, Lindberg A, Albertsson-Wikland K, Wilton P, Price DA, Reiter EO. Increased Response, But Lower Responsiveness, to Growth Hormone (GH) in Very Young Children (Aged 0–3 Years) with Idiopathic GH Deficiency: Analysis of Data from KIGS. J Clin Endocrinol Metab 2005; 90: 1966-1971
    CrossrefPubMedGoogle Scholar
  • 43 Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wüster C. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 1999; 84: 3929-3935
    CrossrefPubMedGoogle Scholar